文献速递白血病淋巴瘤

前列腺凋亡反应蛋白-4肿瘤抑制因子在B细胞慢性淋巴细胞白血病中的新作用

Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia.
PubMed 文献 · Blood · 2018-04-25

研究发现人慢性淋巴细胞白血病(CLL)患者及Eμ-Tcl1小鼠的CLL细胞组成性表达前列腺凋亡反应蛋白-4(Par-4),且高于正常B-1或B-2细胞。敲低Par-4可上调p21/WAF1、延迟G1至S期转换并抑制CLL生长。Par-4表达依赖组成性活跃的B细胞受体(BCR)信号,FDA批准药物抑制BCR信号可降低Par-4并增加凋亡。

要点

  • 人CLL患者及Eμ-Tcl1小鼠的CLL细胞组成性表达Par-4,水平高于正常B-1或B-2细胞。
  • 敲低Par-4上调p21/WAF1,延迟G1至S期转换,抑制人CLL来源Mec-1细胞及Eμ-Tcl1小鼠CLL生长。
  • Par-4表达依赖BCR信号中Lyn、脾酪氨酸激酶和布鲁顿酪氨酸激酶活性,提示Par-4在CLL中可能发挥促生长而非促凋亡作用,或可靶向增强BCR信号抑制剂的疗效。

核心结论

  • Par-4在CLL中可能发挥新的促生长而非促凋亡作用,或可靶向增强BCR信号抑制剂的治疗效果。

研究设计与样本

  • 研究检测人CLL患者及Eμ-Tcl1小鼠CLL细胞中Par-4的表达,并在人CLL来源Mec-1细胞及Eμ-Tcl1小鼠中进行Par-4敲低实验。

主要发现

  • 人CLL患者及Eμ-Tcl1小鼠的CLL细胞组成性表达Par-4,水平高于正常B-1或B-2细胞。
  • 在人CLL来源Mec-1细胞中敲低Par-4,p21/WAF1表达大幅增加,因G1至S期细胞周期转换延迟而生长减少。
  • 在Eμ-Tcl1小鼠中缺乏Par-4亦增加p21表达并延迟CLL生长。
  • CLL细胞中Par-4表达需要组成性活跃的BCR信号,用FDA批准药物抑制BCR信号导致Par-4信使RNA和蛋白降低、凋亡增加。
  • Lyn(Src家族激酶)、脾酪氨酸激酶和布鲁顿酪氨酸激酶的活性是CLL细胞表达Par-4所必需的,提示Par-4经BCR信号受到新调控。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prostate apoptosis response-4 (Par-4), a proapoptotic tumor suppressor protein, is downregulated in many cancers including renal cell carcinoma, glioblastoma, endometrial, and breast cancer. Par-4 induces apoptosis selectively in various types of cancer cells but not normal cells. We found that chronic lymphocytic leukemia (CLL) cells from human patients and from Eµ-Tcl1 mice constitutively express Par-4 in greater amounts than normal B-1 or B-2 cells. Interestingly, knockdown of Par-4 in human CLL-derived Mec-1 cells results in a robust increase in p21/WAF1 expression and decreased growth due to delayed G1-to-S cell-cycle transition. Lack of Par-4 also increased the expression of p21 and delayed CLL growth in Eμ-Tcl1 mice. Par-4 expression in CLL cells required constitutively active B-cell receptor (BCR) signaling, as inhibition of BCR signaling with US Food and Drug Administration (FDA)-approved drugs caused a decrease in Par-4 messenger RNA and protein, and an increase in apoptosis. In particular, activities of Lyn, a Src family kinase, spleen tyrosine kinase, and Bruton tyrosine kinase are required for Par-4 expression in CLL cells, suggesting a novel regulation of Par-4 through BCR signaling. Together, these results suggest that Par-4 may play a novel progrowth rather than proapoptotic role in CLL and could be targeted to enhance the therapeutic effects of BCR-signaling inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. McKenna MK, Noothi SK, Alhakeem SS, et al. Novel role of prostate apoptosis response-4 tumor suppressor in B-cell chronic lymphocytic leukemia. Blood. 2018. PMID: 29695515. doi:10.1182/blood-2017-10-813931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。